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Methods. We used pharmaceutical claims for a random 10% sample of Australians age 18 years or older initiating or reinitiating strong opioid treatment (90 days of no strong opioid dispensing) between July 2010 and December 2012. We report the distribution of opioid access by metric. We used three separate zero-truncated negative binomial regressions to explore associations. We censored individuals 365 days after index date or at death, whichever occurred first.
Results. Approximately 69,088 persons initiated or reinitiated strong opioid treatment; they were predominantly female (59.7%) with a median age of 71 years (interquartile range [IQR] 5 58-81). Over one year, persons visited a median of two prescribers (IQR 5 1-3), visited one dispensing pharmacy (IQR 5 1-2), and had four opioid dispensings (IQR 5 2-10). Three percent of people were in the top decile of opioid access distribution for all three metrics (four or more prescribers, three or more dispensing pharmacies, and 20 or more dispensings). Increasing opioid access was strongly associated with male sex,
Introduction
Over the past two decades, prescription opioid use has increased globally [1] , coinciding with expanding its indication to include the treatment of noncancer as well as cancer pain. At this time, opioid-related harms including hospitalizations and deaths also increased [2] [3] [4] [5] [6] . In recognition of these escalating harms, the US Food and Drug Administration endorsed the postmarket surveillance of opioids using routine data collections [7] , with a particular focus on identifying extramedical use [8] including doctor and pharmacy shopping.
Our recent systematic review synthesized 13 years of international literature attempting to quantify extramedical use of prescription drugs in pharmaceutical claims. In the 52 studies reviewed, number of prescribers, number of dispensing pharmacies, and volume of drugs dispensed were frequently used metrics defining extramedical use [9, 10] , based on the assumption that higher access patterns are likely to be associated with harm to that individual or others. Despite these common metrics, we found 89 unique definitions of extramedical prescription drug use, 57 of which related to opioids. The vast majority of studies dichotomized access behaviors using a specific threshold delineating routine from extramedical use. Definitions of misuse were predominantly based on previously published work, empirical analysis, or expert opinion [9] . Few studies reported the full spectrum of access patterns (lowest to highest) or the determinants of higher access patterns.
The overall objective of this study was to explore the full spectrum of opioid access over a one-year period in Australian adults initiating or reinitiating strong opioid treatment between July 2010 and December 2012. We used national, population-based, person-level pharmaceutical claims to examine the distribution of opioid access in the year following the date of initiating or reinitiating strong opioid treatment across three metrics: number of unique opioid prescribers, number of unique dispensing pharmacies for opioids, and number of opioid dispensings. We also examined the association between patient characteristics and increasing opioid access patterns.
Methods

Setting
Australia has a publicly funded universal health care system entitling its 24 million citizens and permanent residents to a range of subsidized health services, including free treatment in public hospitals, subsidized treatment in private hospitals, and outpatient services, including subsidized prescription drugs via the Pharmaceutical Benefits Scheme (PBS) [11] .
Data Source
This study is part of the POPPY research project, evaluating the patterns and costs of prescription opioid use in Australia [12] . The data supplied by the Department of Human Services comprised the dispensing history of a 10% random sample of persons age 18 years or older initiating or reinitiating strong opioid treatment [13] between July 1, 2009, and December 31, 2013, defined as a strong opioid dispensing after a period of at least 90 days where no strong opioids were supplied.
PBS data capture all dispensings (original and repeats) for PBS-subsidized prescription drugs that attract government subsidy, which occurs when the price of the drug is above the PBS copayment threshold [11] . As such, we have complete ascertainment of concessional beneficiaries' PBS records (persons receiving government benefits including the old age, sickness, unemployment, single-parent or disability pension), as all PBS-subsidized drugs cost more than concessional beneficiaries' copayment amount (2009-2013: AU$5.30-$5.90) [14] . Consequently, we restricted all analyses to concessional beneficiaries. Concessional beneficiaries comprise approximately 25% of the Australian population [15] .
Prescription Opioids of Interest
We used the World Health Organization's Anatomical Therapeutic Chemical (ATC) Classification System code N02A to identify PBS-subsidized opioid analgesics dispensed for the indication of pain (Supplementary Table 1) . We also used the WHO's cancer pain ladder for adults to categorize PBS-listed buprenorphine, fentanyl, hydromorphone, morphine, or oxycodone as strong opioids and the 'mild opioids' codeine and tramadol as weaker opioids [13] .
Study Population
We restricted the study cohort to persons who were concessional beneficiaries for the entire data period (July 1, 2009, to December 31, 2013, inclusive) and initiated or reinitiated strong opioid treatment between July 1, 2010, and December 31, 2012 ( Figure 1 ). By definition, our cohort does not include persons dispensed PBS-subsidized weaker opioids exclusively or persons who do not have a gap in strong opioid dispensings for all or part of the observation period.
We observed cohort members for up to two years, 365 days prior to the date of initiating or reinitiating strong opioid treatment and 365 days from this date (inclusive). We censored persons 365 days after initiating or reinitiating strong opioid treatment or at death, whichever occurred first. If a person had multiple episodes of strong opioid treatment, we report only the first strong opioid treatment episode.
Study Measures
Outcome measures: number of unique opioid prescribers, number of unique dispensing pharmacies for opioids, and number of opioid dispensings recorded up to 365 days after the date of initiating or reinitiating strong opioid treatment (details in Table 1 ). To understand complete opioid access patterns, for each metric we counted all PBS-subsidized opioid dispensings (strong and weaker).
Explanatory variables: on the date of initiating or reinitiating strong opioid treatment, we recorded patient age (years), sex, and location of patient residence (according to Statistical Local Area [SLA]). We used location of patient residence (SLA) as a proxy for residential level of remoteness and relative socioeconomic disadvantage of residence (see previous publications for further details) [12, 16, 17] . In the year prior to initiating or reinitiating strong opioid treatment, we identified treatment for a number of medical conditions using the Rx-Risk tool (hereafter referred to as "Rx-Risk"), a validated measure using 12-month dispensing records to identify the treatment and presence of specific medical conditions (Table 1 and  Supplementary Table 2 ) [18, 19] . We identified separately the conditions of pain/inflammation (nonsteroidal antiinflammatory drug [NSAID]), pain (opioid), and malignancy.
Statistical Analysis
We characterized opioid access over one year for our three outcome measures using descriptive statistics , and malignancy). In each regression model, we did not include either of the other two outcomes as explanatory variables in the models as all three outcomes were highly correlated and we were interested in the independent effects of patient factors on each specific opioid access pattern. For each multivariable model, we reported the incidence rate ratio (IRR) with 95% confidence intervals (CIs). We censored persons 365 days from initiating or reinitiating strong opioid treatment (inclusive) or at death; whichever occurred first. In our data, we received date of death as month and year of death, therefore, the precise temporal relationship between death and dispensing date are unknown. We therefore excluded persons who died in the same month as the date of initiating or reinitiating strong opioid treatment (N ¼ 2,606) and conducted sensitivity analyses to assess the impact of this decision.
We used SAS software version 9.4 (SAS Institute, Cary, NC, USA) for all analyses.
Ethics approval
The Population and Health Services Research Ethics Committee approved this project (2013/10/481).
Results
Cohort Demographics
We identified 69,088 concessional beneficiaries initiating or reinitiating strong opioid treatment between July 1, In the year prior to initiating or reinitiating strong opioid treatment, two-thirds (67.7%) of the cohort were dispensed prescription drugs to treat three or more medical conditions and over one-quarter (29.3%) were treated for at least six medical conditions (excluding pain/inflammation [NSAID], pain [opioid], and malignancy). Only 4.4% were previously dispensed drugs to treat malignancy. Almost half (43.3%) were dispensed drugs for pain (opioid; includes both strong and weaker opioids) treatment in the three to 12 months prior to initiating or reinitiating strong opioid treatment. In the year prior to initiating or reinitiating strong opioid treatment, 60.2% of the cohort were dispensed an NSAID or paracetamol.
Opioid Use and Access Patterns
There were 530,215 opioid dispensing episodes for the cohort in the year after initiating or reinitiating strong opioid treatment. Oxycodone, buprenorphine, and codeine together comprised more than 75% of opioid dispensings (42.1%, 20.2%, and 14.9%, respectively). To access all opioids (strong and weaker), persons visited a median of two unique prescribers (IQR ¼ 1-3), visited one dispensing pharmacy (IQR ¼ 1-2), and received four opioid dispensings (IQR ¼ 2-10) (Figure 2 ). Over half the cohort (52.4%) visited one or two prescribers and one dispensing pharmacy to access opioids over one year; these persons obtained a median of two opioid dispensings (IQR ¼ 1-4). At the other end of the spectrum, the 90th centile for each metric was four prescribers, three dispensing pharmacies, and 20 dispensings. In the cohort, 13.4% (N ¼ 9,261) visited four or more prescribers, 17.2% (N ¼ 11,894) visited three or more dispensing pharmacies, and 10.7% (N ¼ 7,418) obtained 20 or more dispensings; only 3.1% (N ¼ 2,151) were in the top decile for all three metrics ( Figure 3 ).
Factors Associated with Increasing Opioid Access Patterns
We stratified access patterns for number of unique prescribers, dispensing pharmacies, and dispensings by individual factors and opioid dispensings over one year (Table 3A-C) . As the value for each metric increased, the proportion of persons who exhibited the pattern decreased. For example, 47.4% of the cohort visited one prescriber whereas only 0.6% visited 10 or more prescribers. Generally, as the value for each metric increased, so did the proportion of persons with a history of treatment for pain/inflammation (NSAID; one dispensing: 26.4% to 39.5% for 31 dispensings) or pain (opioid; one prescriber: 34.1% to 75.3% for 10 prescribers).
The relationship with other patient factors varied by metric. As the number of prescribers or dispensing pharmacies increased, the median age and median number of medical conditions decreased. For example, the median age was higher for persons accessing one pharmacy (73; IQR ¼ 61-82) compared with persons accessing 10 or more pharmacies (40; IQR ¼ 34-49), whereas for dispensings, as the number of dispensings increased, both the median age and median number of conditions increased.
Finally, persons who visited at least three prescribers, visited at least two dispensing pharmacies, or obtained at least eight dispensings obtained disproportionately large amounts of opioids, that is, the proportion of dispensed opioids obtained was larger than the proportion of persons exhibiting the access pattern (Table 3A-C) . This became particularly marked as the threshold increased; for example, 13.3% of persons visited four or more prescribers but obtained almost one-third (32.6%, N ¼ 172,797) of all opioid dispensings.
Our descriptive results were largely consistent with the multivariable regression analyses (Table 4) . We found males were 6% to 13% more likely to exhibit increasing opioid access patterns compared with females. Older persons (45 years) accessed fewer prescribers and pharmacies than younger persons (18-44 years) but obtained more opioid dispensings. Persons living in regional or remote areas visited more prescribers but fewer pharmacies than persons living in a major city. There was limited evidence that relative socioeconomic disadvantage of residence was associated with any outcome after adjusting for other factors.
Across all outcomes, the strongest factors associated with increasing opioid access patterns were a history of pain (opioid) or malignancy treatment. We found limited associations between a history of pain/inflammation (NSAID) treatment and increasing opioid access patterns after adjusting for other factors. For all three outcomes, persons with an increasing number of medical conditions had higher access patterns than their counterparts with fewer medical conditions. Of note, our descriptive analysis demonstrated a decrease in median number of medical conditions as the number of prescribers or dispensing pharmacies increased; controlling for age in the multivariable regression analyses reversed the direction of this association. In all analyses, we excluded persons who died in the same month as initiating or reinitiating strong opioid treatment (N ¼ 2,606). We conducted a sensitivity analysis to explore the impact of this decision by replicating our three zero-truncated negative binomial multivariable regression analyses and including these persons. The results for these sensitivity analyses were almost identical to our original results for number of prescribers and dispensing pharmacies (Supplementary Table 3 ). However, the incidence risk ratio (IRR) of obtaining multiple opioid dispensings increased considerably for persons age 85 years or older and persons with a history of malignancy treatment.
Discussion
In this cohort, the majority of people initiating or reinitiating strong opioid treatment exhibited unremarkable access patterns. Specifically, over two-thirds of the cohort visited one or two prescribers or dispensing pharmacies over one year to access their prescription opioids. These people obtained two-fifths of all dispensed opioids and had a median of two opioid dispensings over one year.
In our systematic review quantifying extramedical use of prescription drugs in pharmaceutical claims, only six of the 52 reviewed studies reported the distribution of prescription drug access for at least one metric [9] . To date, only three studies, all from the United States, have reported the spectrum of opioid access patterns over one year using pharmaceutical claims [21] [22] [23] . These studies reported that 83% to 92% of persons visited one or two opioid prescribers over one year [21, 22] and 52% to 98% visited up to two pharmacies [22, 23] . The difference in proportions reflects the cohort definition; studies with a more restrictive inclusion criteria, such as three months of continuous opioid use prior to index date, generally report lower proportions of persons visiting one to two prescribers/dispensing pharmacies.
There is considerable variation in the extent of extramedical opioid use reported across studies. In our systematic review, we found the extent of extramedical opioid use ranged from less than 1% to 63.2%, with similar figures (<1% to 81%) reported in a recent review examining extramedical opioid use in adults with chronic pain [10, 24] . In our review, estimates were dependent on the use of single or combined metrics and thresholds delineating routine use from extramedical use. Generally, when extramedical use is defined using higher thresholds and/or multiple metrics, the reported level of misuse is lower. In the current study, over onequarter of the cohort exhibited access patterns in the top decile for at least one metric (four or more prescribers, three or more pharmacies, or 20 or more dispensings). Based on our review of previous literature, any one of these access patterns would have been considered extramedical use [9] .
In our study, 3% of persons exhibited access patterns in the top decile for all three metrics. Compared with the entire cohort, these persons were younger (52% aged 18-64 years) and obtained a disproportionately large amount of opioid dispensings (14%). These characteristics were consistent with previous literature profiling "misusers" [25] . Compared with the entire cohort, persons who exhibited access patterns in the top decile for all three metrics also had a higher proportion of history of malignancy treatment (7% vs 4%) and a higher median number of medical conditions (6 vs 3). These findings were consistent with a recent US Medicare study; as the number of prescribers increased, so did the proportion of persons dispensed antineoplastic, stimulant, central nervous system, neuromuscular, and nonopioid analgesic drugs [21] . These findings suggest sicker persons have increasing opioid access, which may be consistent with routine medical care rather than extramedical use. However, disease severity is difficult to determine based on pharmaceutical claims alone; only the treating physician would have all the information necessary to assess whether the volume of drugs procured from visiting multiple doctors and pharmacies were for legitimate medical or extramedical purposes.
Our study had several limitations. As with previous studies included in our systematic review, we have focused on access patterns and therefore potential risk of harm that could be attributed to higher patterns of use. These studies, which rely solely on dispensing claims, do not have the capacity to identify harms with normal use, for example, excessive sedation occurring with initiation. Moreover, our cohort was restricted to initiators and reinitiators of strong opioid treatment, and thus excluded most long-term strong opioid use. We classified each opioid as strong or weaker based on the World Health Organization cancer pain guidelines for adults. This dichotomy is generally reflected in prescription choices, scheduling, and availability, but oversimplifies complex pharmacological differences within the class in efficacy, safety, mechanisms, and potency. We restricted our cohort to concessional beneficiaries (persons receiving a government pension) as we have their complete PBS dispensing history. Our data did not capture any under-copayment dispensings or private prescriptions, which together accounted for 18% of opioid use in 2011 [26] . Further, our data did not capture dispensings for non-PBS-listed prescription opioids, including dextropropoxyphene and tapentadol, nor over-thecounter (OTC) codeine (only OTC opioid available in Australia), which accounted for at least 56% of all prescription and OTC codeine sales in 2013 [27, 28] . Therefore, our results underestimate total opioid use and access patterns. Moreover, our previous research demonstrated the length of the look-back period impacts on the formation of cohorts in new-user study designs [29] . However, we previously demonstrated that the POPPY cohort demographics were similar whether we adopted a 3-, 6-, or 12-month opioid-free period [16] .
Conclusion
Despite the recent push to quantify extramedical opioid use via routinely collected health data, this study demonstrated the challenges in delineating routine from extramedical use based on pharmaceutical claims alone. Pharmaceutical claims have utility in examining population norms of prescription drug use and access patterns, and flagging persons at the extreme end of access, for at least one measure, who may warrant further investigation.
